Aratana Therapeutics, Inc. (NASDAQ:PETX)

CAPS Rating: 2 out of 5

Results 1 - 4 of 4

Recs

0
Member Avatar NHWeston102 (< 20) Submitted: 2/5/2016 1:11:16 PM : Outperform Start Price: $3.32 PETX Score: -18.07

Credit Suisse sees a turn-around coming. This is a bet on petcare company, a subcategory of bio-pharma relatively immune to political currents.

Recs

0
Member Avatar stockgripes (99.09) Submitted: 9/28/2015 1:57:57 PM : Outperform Start Price: $7.86 PETX Score: -64.93

nothing to loose

Recs

0
Member Avatar TurbulentTime (< 20) Submitted: 9/11/2014 1:42:04 PM : Outperform Start Price: $11.45 PETX Score: -69.95

In the long run, PETX will see increasing revenue. For now, as of Sept 2014, it still doesn't have no real revenue yet as it is still in the process of getting drug approval.

Recs

0
Member Avatar asilverp (70.79) Submitted: 8/29/2014 1:17:11 PM : Underperform Start Price: $11.61 PETX Score: +69.91

price is 550 times sales. Looks like a classic story stock to me. Everyone loves pets. How could you go wrong with a stock that markets to them? Probably worth < 1$.

Results 1 - 4 of 4

Featured Broker Partners